Swiss Sonova is having issues with defective cochlear implants, writes the domestic newspaper NZZ am Sonntag. According the Swiss media, implants will have to be surgically removed from several patients.
The news wasn't received well on Monday morning, as evident on the stock exchange in Zürich. Sonova stock decreased in value by 2 percent to CHF 383 (USD 419) after the news broke.
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.